DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; Acetylcysteine; Adenosine; Air; Alcohol; Antiarrhythmic drugs; Atorvastatin; BNP; BNP blood sample test; Behavioral: Lifestyle; Bluefish; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CK-3773274; CK-3773274 (10 - 30 mg); CK-3773274 (5 - 15 mg); CK-3773274 - Granules in Capsule; CK-3773274 - Tablets; CT-G20; Candesartan; Carnitine; Cufence; Cyclosporine; Cyclosporine A; Device: Insertable cardiac monitor; Device: Magnetic resonance imaging (MRI) with gadolinium enhancement; Device: Magnetic resonance imaging (MRI) without gadolinium enhancement; Device: Use of bioanalytical assay to monitor plasma levels of perhexiline; Diagnostic Test: Air venous plethysmography; Diagnostic Test: Echocardiography; Diagnostic Test: Electrocardiogram; Diagnostic Test: Exercise Stress Transthoracic Echocardiogram; Diagnostic Test: Holter ECG; Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy; Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD; Diltiazem; Diovan; Diovan 160 mg; Diovan 40 mg; Diovan 80 mg; Dobutamine; Echo and myocardial contrast echocardiography perfusion imaging; Eleclazine; Endothelial function biomarkers; Entresto; GS-6615 3 mg; GS-6615 3 mg Pink; GS-6615 3 mg White; GS-6615 6 mg; GS-6615 6 mg White; Gadolinium; Gradient; Gutron 2,5mg; Gutron 5mg; Hyperpolarized 13C-Pyruvate; LCZ696; LCZ696 100 mg; LCZ696 200 mg; LCZ696 50 mg; Losartan; Losartan Bluefish 50 mg; MAVACAMTEN; MEK162; MIDODRINE HYDROCHLORIDE; MONITOR; MYK-461; Mangafodipir; Mavacamten; Metoprolol; Metoprolol Succinate; Midodrine; N-acetylcysteine; Nitrate; Other: Exercise echocardiography; Other: Mangafodipir trisodium; Other: Walk distance test; Perhexiline; Perxexiline; Pexsig; Phosphorous; Piperazine; Pirfenidone; Procedure: 3D electrocardiographic mapping (ECM); Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Echocardiography (TEE); Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: RF catheter ablation; Procedure: trans-right ventricular alcohol septal ablation (TRVASA); Pyrazole; RANEXA; RANEXA*60CPR 500MG R.P.; RANEXA*60CPR 750MG R.P.; RANOLAZINE; Ranexa; Ranolazine; Ranolazine 1000 mg PR tablets; Ranolazine 500 mg PR tablets; Ranolazine 750 mg PR tablets; Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; Regadenoson; SACUBITRIL VALSARTAN; Sacubitril; Sacubitril/Valsartan; Sacubitril/valsartan; Sodium Nitrate; Sodium nitrate; Spironolactone; Treatment BX1514M; Trientine; Trientine Dihydrochloride; Trientine dihydrochloride; Triethylinetetramine dihydrochloride; Trimetazidine; Trimetazidine Dihydrochloride 20mg; Trimetazidine dihydrochloride; VALSARTAN; Valsartan; Vastarel; Vastarel 20mg film coated tablets; [MYK-461]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003098-24-GB (EUCTR)	30/04/2020	21/02/2020	Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy	A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)	non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	44	Phase 2	United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of
2	EUCTR2019-003098-24-GR (EUCTR)	16/04/2020	13/04/2020	Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy	A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)	non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	44	Phase 2	United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of
3	EUCTR2019-003098-24-FI (EUCTR)	15/04/2020	02/03/2020	Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy	A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)	non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	44	Phase 2	United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of
4	EUCTR2019-003098-24-ES (EUCTR)	19/02/2020	02/12/2019	Study of efficacy of oral sacubitril/valsartan adult patients with non-obstructive hypertrophic cardiomyopathy	A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)	non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	44	Phase 2	United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of
5	NCT04164732 (ClinicalTrials.gov)	January 8, 2020	13/11/2019	Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy	A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM)	Cardiomyopathy, Hypertrophic	Drug: LCZ696;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	44	Phase 2	United States;Finland;Germany;Greece;Korea, Republic of;Spain
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2019-003098-24-DE (EUCTR)	18/12/2019	05/11/2019	Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy	A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)	non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril /valsartan Other descriptive name: SACUBITRIL VALSARTAN	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	44	Phase 2	United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of
7	NCT03832660 (ClinicalTrials.gov)	May 3, 2019	1/2/2019	Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy	Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy	Hypertrophic Cardiomyopathy	Behavioral: Lifestyle;Drug: Sacubitril /Valsartan	Newcastle University	Azienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of Belgrade	Recruiting	18 Years	70 Years	All	240	Phase 2	Germany;Italy;Serbia;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-003098-24-GB
(EUCTR)

30/04/2020

21/02/2020

Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy

A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM)

non-obstructive hypertrophic cardiomyopathy
MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Trade Name: Entresto
Product Name: LCZ696 50 mg
Product Code: LCZ696
INN or Proposed INN: sacubitril /valsartan
Other descriptive name: SACUBITRIL VALSARTAN
Trade Name: Entresto
Product Name: LCZ696 100 mg
Product Code: LCZ696
INN or Proposed INN: sacubitril /valsartan
Other descriptive name: SACUBITRIL VALSARTAN
Trade Name: Entresto
Product Name: LCZ696 200 mg
Product Code: LCZ696
INN or Proposed INN: sacubitril /valsartan
Other descriptive name: SACUBITRIL VALSARTAN

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of

EUCTR2019-003098-24-GR
(EUCTR)

16/04/2020

13/04/2020

Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of

EUCTR2019-003098-24-FI
(EUCTR)

15/04/2020

02/03/2020

Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of

EUCTR2019-003098-24-ES
(EUCTR)

19/02/2020

02/12/2019

Study of efficacy of oral sacubitril/valsartan adult patients with non-obstructive hypertrophic cardiomyopathy

non-obstructive hypertrophic cardiomyopathy
MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Novartis Farmacéutica, S.A.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of

NCT04164732
(ClinicalTrials.gov)

January 8, 2020

13/11/2019

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM)

Cardiomyopathy, Hypertrophic

Drug: LCZ696;Drug: Placebo

Novartis Pharmaceuticals

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States;Finland;Germany;Greece;Korea, Republic of;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-003098-24-DE
(EUCTR)

18/12/2019

05/11/2019

Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy

Novartis Pharma AG

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of

NCT03832660
(ClinicalTrials.gov)

May 3, 2019

1/2/2019

Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy

Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Behavioral: Lifestyle;Drug: Sacubitril /Valsartan

Newcastle University

Azienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of Belgrade

Recruiting

18 Years

70 Years

All

240

Phase 2

Germany;Italy;Serbia;United Kingdom